The two targets of anti-CD19/CD22 CAR T cells, CD19 and CD22, are commonly expressed on B cell lymphomas, whereas those receptors are not expressed on other cell types including hematopoietic stem cells.150. The gene discussed is CD22; the disease is B-cell non-Hodgkin lymphoma.